Overview

* AngioDynamics ( ANGO ) fiscal Q4 net sales rose 12.7%, beating analyst expectations, per LSEG data

* Adjusted EPS for fiscal Q4 beat analyst estimates, per LSEG data

* Co generated $16.2 mln free cash flow in Q4 due to strong growth

Outlook

* AngioDynamics ( ANGO ) sees FY2026 net sales $305 - $310 mln

* Company expects Med Tech net sales growth of 12% - 15%

* AngioDynamics ( ANGO ) forecasts flat Med Device net sales growth

* Company anticipates FY2026 gross margin 53.5% - 55.5%

Result Drivers

* MED TECH GROWTH - AngioDynamics ( ANGO ) reported a 22% increase in Med Tech net sales, driven by innovative platform technologies, per CEO Jim Clemmer

* OPERATIONAL EFFICIENCY - Positive adjusted EBITDA and $16.2 million free cash flow attributed to operational efficiency efforts

* TARIFF HEADWINDS - Tariffs impacted gross margin by 204 basis points, but strategies are in place to mitigate future impacts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Sales Beat $80.20 $74.30

mln mln (3

Analysts

)

Q4 Beat -$0.03 -$0.12

Adjusted (3

EPS Analysts

)

Q4 Beat -$1 mln -$4.97

Adjusted mln (3

Net Analysts

Income )

Q4 Net -$6.10

Income mln

Q4 $3.40

Adjusted mln

EBITDA

Q4 Gross 52.7%

Margin

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for AngioDynamics Inc ( ANGO ) is $16.00, about 39.8% above its July 14 closing price of $9.63

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)